The effects of the farnesyl transferase inhibitor FTI L-778,123 on normal, myelodysplastic, and myeloid leukemia bone marrow progenitor proliferation in vitro

X. K. Huang, P. Meyer, B. Li, A. Raza, H. D. Preisler

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

The effects of the farnesyl transferase inhibitor FTI-778,123 on the proliferation of normal, MDS, AML, and CML hemopoietic progenitor cells was studied. MDS myeloid and erythroid progenitors are significantly more sensitive to FTI than normal progenitors while AML myeloid progenitors may be somewhat more sensitive than normal progenitors. In contrast, no difference between CML and normal progenitors are detectable. These data strongly suggest that a trial of this agent in patients with MDS and perhaps in patients with AML is indicated.

Original languageEnglish (US)
Pages (from-to)157-164
Number of pages8
JournalLeukemia and Lymphoma
Volume44
Issue number1
DOIs
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Myeloid Leukemia
Proxy
Transferases
Stem Cells
Bone Marrow
In Vitro Techniques

Keywords

  • Bone marrow progenitor cells
  • FTI L-778,123
  • Farnesyl transferase inhibitor
  • Myelodysplasia
  • Myeloid leukemia
  • Normal progenitors

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

The effects of the farnesyl transferase inhibitor FTI L-778,123 on normal, myelodysplastic, and myeloid leukemia bone marrow progenitor proliferation in vitro. / Huang, X. K.; Meyer, P.; Li, B.; Raza, A.; Preisler, H. D.

In: Leukemia and Lymphoma, Vol. 44, No. 1, 01.01.2003, p. 157-164.

Research output: Contribution to journalReview article

@article{e9520cfdaafe4c21abcf7538594dde85,
title = "The effects of the farnesyl transferase inhibitor FTI L-778,123 on normal, myelodysplastic, and myeloid leukemia bone marrow progenitor proliferation in vitro",
abstract = "The effects of the farnesyl transferase inhibitor FTI-778,123 on the proliferation of normal, MDS, AML, and CML hemopoietic progenitor cells was studied. MDS myeloid and erythroid progenitors are significantly more sensitive to FTI than normal progenitors while AML myeloid progenitors may be somewhat more sensitive than normal progenitors. In contrast, no difference between CML and normal progenitors are detectable. These data strongly suggest that a trial of this agent in patients with MDS and perhaps in patients with AML is indicated.",
keywords = "Bone marrow progenitor cells, FTI L-778,123, Farnesyl transferase inhibitor, Myelodysplasia, Myeloid leukemia, Normal progenitors",
author = "Huang, {X. K.} and P. Meyer and B. Li and A. Raza and Preisler, {H. D.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1080/1042819021000040387",
language = "English (US)",
volume = "44",
pages = "157--164",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - The effects of the farnesyl transferase inhibitor FTI L-778,123 on normal, myelodysplastic, and myeloid leukemia bone marrow progenitor proliferation in vitro

AU - Huang, X. K.

AU - Meyer, P.

AU - Li, B.

AU - Raza, A.

AU - Preisler, H. D.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - The effects of the farnesyl transferase inhibitor FTI-778,123 on the proliferation of normal, MDS, AML, and CML hemopoietic progenitor cells was studied. MDS myeloid and erythroid progenitors are significantly more sensitive to FTI than normal progenitors while AML myeloid progenitors may be somewhat more sensitive than normal progenitors. In contrast, no difference between CML and normal progenitors are detectable. These data strongly suggest that a trial of this agent in patients with MDS and perhaps in patients with AML is indicated.

AB - The effects of the farnesyl transferase inhibitor FTI-778,123 on the proliferation of normal, MDS, AML, and CML hemopoietic progenitor cells was studied. MDS myeloid and erythroid progenitors are significantly more sensitive to FTI than normal progenitors while AML myeloid progenitors may be somewhat more sensitive than normal progenitors. In contrast, no difference between CML and normal progenitors are detectable. These data strongly suggest that a trial of this agent in patients with MDS and perhaps in patients with AML is indicated.

KW - Bone marrow progenitor cells

KW - FTI L-778,123

KW - Farnesyl transferase inhibitor

KW - Myelodysplasia

KW - Myeloid leukemia

KW - Normal progenitors

UR - http://www.scopus.com/inward/record.url?scp=0037234811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037234811&partnerID=8YFLogxK

U2 - 10.1080/1042819021000040387

DO - 10.1080/1042819021000040387

M3 - Review article

VL - 44

SP - 157

EP - 164

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -